Press release
Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Oncology Biosimilars Market Research Report: Ken Research
According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is predicted to increase at a compound annual growth rate (CAGR) of 33.17% and reach USD 9404.54 million by 2023.
The pharmaceutical companies are progressively investing in research and development to introduce the new oncology biosimilars. The corporates are exploiting growth impending of increasing the biosimilar market by participating in their research and development (R&D) procedures to support the research and production process of fresh biosimilars. For instance, during the fiscal year 2017, Aurobindo Pharma spent USD 80 million to assist the research for the biosimilars involving oncology biosimilars. Also, during 2019, Biocon, India's greatest biotechnology company contributed to obtain some assets of Pfizer Healthcare to set up R&D facility to boost biosimilar improvement.
In addition, the foremost players in the market are Biocoin, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH and BIOCAD. While, the shortage of awareness on biosimilars among primary care physicians (PCPs) and specialist restricts the growth of the oncology biosimilars market. Biosimilars are produced from cell lines and offer the similar helpfulness as biologics. However, shortage of detailed mindfulness on the biosimilars amongst the prescribers decreases the prescriptions of biosimilars disturbing the biosimilar market.
For instance, as reported during 2018 by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unaccustomed with biosimilars and 35% were reluctant to advise them owing to concerns included protection of the follow-on biologic. Thus, the shortage of awareness about biosimilars amongst the primary care physicians (PCPs) and specialists limits the growth of the oncology biosimilars market.
Whereas, the expiration of patent of biologics optimized for the treatment of cancer is propelling the production of fresh oncology biosimilars. Biologics can be unproved for a limited duration and the expiration of patents for biologics enables the improvement of new biosimilars. Biologics are embattled drugs synthesized from living organisms which encourages the immune system to outbreak cancer cells. Biosimilars are similar to biologics but are not matching and offers the same helpfulness as biologics at a decreased cost.
According to the Center for Biosimilars, patents on approximately 20 oncology biologics will decease by 2023, leading to the improvement of new biosimilars in cancer care. The augmented number of patent expiry is probable to boost the requirement for the production of fresh oncology biosimilars, thus, propelling the market growth for oncology biosimilars. Therefore, in the near years, it is anticipated that the market of oncology biosimilars will increase around the globe more effectively over the forthcoming years.
For More Information, Click on the Link Below:-
https://www.kenresearch.com/healthcare/pharmaceuticals/oncology-biosimilars-market/342064-91.html
Related Reports:-
https://www.kenresearch.com/healthcare/general-healthcare/oncology-biosimilars-market/288736-91.html
https://www.kenresearch.com/healthcare/pharmaceuticals/oncology-biosimilars-market/247255-91.html
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
Ken Research Pvt. Ltd.,
Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49 Gurgaon, Haryana - 122001, India
Ken Research is a Global aggregator and publisher of Market intelligence, equity and economy reports. Ken Research provides business intelligence and operational advisory in 300+ verticals underscoring disruptive technologies, emerging business models with precedent analysis and success case studies. Serving over 70% of fortune 500 companies globally, some of top consulting companies and Market leaders seek Ken Research’s intelligence to identify new revenue streams, customer/ vendor paradigm and pain points and due diligence on competition.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Oncology Biosimilars Market Research Report: Ken Research here
News-ID: 2232528 • Views: …
More Releases from Ken Research Pvt Ltd
Increase in cybercrime results in India Digital Forensic Market to rise, with an …
With the rise in digital threats and cybercrimes, India Digital Forensic Market makes successive changes like integration of Artificial Intelligence, and marking its overall growth.
STORY OUTLINE
Using techniques like Data Recovery, Log Analysis and more, India Digital Forensic Market enhances its Computer Forensics.
Upgrades towards Network and Mobile Forensics are improving in cyber threats prevention, marking its increase in efficiency and security.
With the incorporation of Cloud Based services, advanced methods and easy…
Global Health Insurance market is expected to grow at a CAGR of ~6% by 2028: Ken …
Due to recent pandemic of Covid 19 health insurance market has grabbed growth ensuring economic help to comman man for better health care facilities with easy money handling and increasing awareness especially after COVID 19.
STORY OUTLINE
Launch of new policies, mergers, acquisitions and partnerships to propel growth in future
Covid 19 has a huge impact on the health insurance market on Global level.
Factors, which are responsible for the growth, are the higher…
Exploring the Investment Landscape in the UK Agricultural Equipment Market
Anticipated to achieve a CAGR of approximately 3.5% (2022-2027), the UK's agricultural equipment market expanded between 2014 and 2018, yet faced a significant downturn in 2019-2020 due to COVID-19.
STORY OUTLINE
The investment landscape in the UK agricultural equipment market is diverse, offering a spectrum of opportunities from established manufacturers to startups driving disruptive change.
Investors can benefit from the technological prowess of leading manufacturers like John Deere, CNH Industrial, and AGCO Corporation…
Unveiling the Thriving Landscape of UAE's IT Service Market
The IT services sector encompasses a diverse range of offerings, including but not limited to Cloud services, Cloud Applications, Datacenters, Artificial Intelligence (AI), Consulting Services, Connectivity Solutions, Security services, and other related services.
STORY OUTLINE
Digital Transformation Drive: UAE's IT market thrives on visionary government initiatives like "Smart Dubai" and "UAE Vision 2021," spurring sectoral evolution.
Cloud's Ascendancy: Rapid cloud adoption, coupled with AI, IoT, and blockchain, reshapes industries for scalability and innovation.
Security…
More Releases for Biosimilars
Global Biosimilars Market 2021-2028 | Price Advantage of Biosimilars Over Biolog …
The global Biosimilars market focuses on encompassing major statistical evidence for the Biosimilars industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition, the Biosimilars study also shifts its attention with an in-depth…
Growth of the Biosimilars Market Is Mainly Driven by Increasing Number of Approv …
A biosimilar is a biologic medical product that is similar to another already approved biological medicine, in terms of quality, safety, and efficacy. Biosimilars are a class of therapeutic drugs that provide additional treatment options and help reduce healthcare costs. Thus, there is an increasing demand for biosimilar drugs due to increasing prevalence of autoimmune diseases, key factor driving the growth of the biosimilars market. According to the National Stem…
Global Biosimilars Market | Global Biosimilars Industry | Global Biosimilars Mar …
The biosimilars market involves of sales of biosimilars and associated services that are cast-off to treat chronic sicknesses such as diabetes, arthritis, and cancer. The Biosimilars are pharmaceuticals that are produced using cell lines and offers no clinical difference as linked to biologics. The Biosimilars are made once the patent of biologics is deceased.
According to the report analysis, ‘Biosimilars Market Global Report 2020-30’ states that the worldwide biosimilars market was…
Global Oral Biologics and Biosimilars Market | Global Oral Biologics and Biosimi …
The oral biologics and biosimilar market contain of sales of oral biologics and biosimilar products and associated services utilized to treat chronic syndromes such as diabetes, arthritis, cancer. Biologics are drugs completed from living cells using exceedingly complex technology while biosimilars are generated to function similarly to biologics but are not matching to biologics. Biosimilars offer energetic properties as any licensed biologic drug. The oral biologics and biosimilar market encompass…
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million…
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American…
